Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

INDIANAPOLIS, June 14, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriati... Biopharmaceuticals Eli Lilly, psoriatic arthritis, Taltz, ixekizumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news